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Abstract
Heart failure with preserved ejection fraction (HFpEF) is now recognized as a major and 
growing public health problem worldwide. This heart failure subtype disproportion-
ately affects women and the elderly and is commonly associated with other cardiovas-
cular comorbidities, such as hypertension, diabetes and chronic kidney disease. There 
are uncertainties and debates regarding the definition, diagnosis and pathophysiology 
with the consequence that all outcome trials performed so far cannot yield an effective 
treatment as in heart failure with reduced ejection fraction (HFrEF). Here we present 
an overview of epidemiology, pathophysiology, diagnosis and therapeutic approaches 
emerging from large outcome clinical trials.
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1. Introduction
Heart failure (HF) is a clinical syndrome of dyspnea, fatigue and fluid retention secondary to 
impaired cardiac function [1]. Cardiac function may be impaired structurally or functionally 
with resultant decreased ejection or filling capacity both of which can reduce cardiac output 
and/or increase intracardiac pressures at rest or during exercise. Systolic dysfunction leading 
to reduced left ventricular ejection fraction (LVEF) (LVEF < 40%) had long been believed to be 
the predominant cause of heart failure. However, HF remains to be a growing health prob-
lem in the community despite recent improvements in the management of HF with reduced 
ejection fraction (HFrEF). Another subset of heart failure which occurs in the setting of nor-
mal or near normal left ventricular ejection fraction (LVEF > 50%) has been evolving for the 
last two decades. This distinct HF subtype has been called HF with preserved ejection frac-
tion (HFpEF). Once included in HFpEF, the newly defined HF with midrange EF (HFmrEF) 
comprises the HF patients with EF between 40 and 50% [2]. HFmrEF will be discussed in 
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the context of HFPEF because most of the trials and epidemiological studies to date have 
included patients with EF > 40%.
Current data indicate that at least half of the HF population has a normal or near-normal 
LVEF [3]. Even more striking is the finding that the percent of patients with HFpEF appears 
to be increasing in relation to the percent that have HFrEF [4]. One of the reasons for this shift 
in the ratio between HFpEF and HFrEF is related to the greater availability of therapeutic 
interventions that limit myocardial damage (particularly, in the setting of an acute myocardial 
infarction), hence reducing incidence of HFrEF. Another important reason for this increase in 
prevalence of HFpEF is increasing number of obese and elderly patients. It is also worth men-
tioning that there is an increased number of patients with possible misdiagnosis of HFpEF 
who have otherwise alternative causes for their symptoms such as obesity, lung disease and 
myocardial ischemia [5].
In the past, HFpEF was thought to be a benign condition, but now it is well known that 
it causes substantial morbidity and mortality [6]. Despite being an enormous and dreadful 
problem of this era, there has been little progress in developing effective treatments that will 
alter the natural history of the condition. Contemporary medicine can offer nothing but only 
diuretic for treatment. This is partly due to an incomplete understanding of the disease and 
partly due to the huge diversity of clinical phenotype.
2. Epidemiology
Over 90% of patients with HFpEF are aged ≥60 years at the time of diagnosis making it obvi-
ous that this is a disease of elderly [7]. The prevalence in the community has varied from 1.1% 
to 5.5% of the general population [8]. This wide variation is primarily attributed to the differ-
ent cutoff values of normal EF in different studies. Moreover, the prevalence has been found 
to vary with age and gender. A large community-based study found that the prevalence of 
HFpEF increased from 0% in males to 1% in females in the age group of 25–49 years to 4–6% 
in males and 8–10% in females above 80 years, indicating a dramatic rise in the prevalence 
with increasing age but additionally a higher prevalence among females as compared to age-
matched males [9]. The demographic characteristics present in patients with HFpEF differ 
significantly from those in patients with HFREF. Compared with those with HFrEF, patients 
with HFpEF are older, more often female, more often have hypertensive heart disease and 
less often have ischemic heart disease [10]. There is a similar prevalence of DM but remark-
ably higher prevalence of obesity in patients with HFpEF compared to HFrEF. Atrial fibrilla-
tion (AF) is also more prevalent in HFpEF [11]. HFpEF patients also have a higher burden of 
both cardiovascular and non-cardiovascular comorbid diseases. Table 1 summarizes various 
comorbidities usually seen in association with HFpEF. Comorbid conditions especially renal 
insufficiency and atrial fibrillation may be less common in randomized controlled trials than 
hospital-based registries due to exclusion criteria.
Whether overall mortality rates differ between patients with HFpEF and HFrEF is not clear. 
Some community-based epidemiological studies have shown that the annual mortality rate is 
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same and approaches 15% for both groups of patients [4]. Conversely, data from randomized 
clinical trials suggest that patients with HFpEF have a lower annual mortality (approaching 
5%) than patients with HFrEF. The lower mortality rate detected in the randomized trials can be 
explained by strict exclusion of comorbid diseases [12]. When the data from I-PRESERVE (The 
Irbesartan in Heart Failure With Preserved Ejection Fraction Study) trial was analyzed with 
respect to mode of death in HFpEF, it was seen that cardiovascular (CV) diseases (60%) are the 
leading cause of death including sudden cardiac death (26%), HF (15%), myocardial infarction 
(5%) and stroke (9%) followed by non-CV causes (30%) and unknown (10%) [13]. Compared 
with HFrEF [14], HFpEF patients have more non-cardiovascular (30% vs. 15%), fewer sud-
den (26% vs. 40%) and fewer heart failure deaths (15% vs. 35%). In parallel with I-PRESERVE 
trial results, the cause-specific mortality estimates show that the non-cardiovascular causes 
of death constitute nearly 30 to 50% of all deaths in HFpEF patients while only 15–18% in 
HFrEF patients [15]. The older age and high burden of comorbidities can explain the higher 
non-cardiovascular mortality in HFpEF patients. Large HFpEF trials showed that the patients 
with HFpEF have lower hospitalization rates than those with HFrEF [16]. Furthermore, HFrEF 
patients have nearly 1% absolute higher in-hospital mortality rate than HFpEF patients [17].
3. Pathophysiology
In contrast to HFrEF patients who have main abnormalities in systolic function, left ventricu-
lar dilation and eccentric remodeling, patients with HFpEF have main abnormalities in dia-
stolic function, normal left ventricular size and concentric hypertrophy. Normal LVEF does 
not imply normal cardiac output. In HFrEF, decreased cardiac output can be explained more 
easily with reduced ejection fraction and subsequent reduced stroke volume. HFpEF patients 
also exhibit a low cardiac output that is comparable to that seen in HFrEF patients. The patho-
physiological abnormality leading to decreased cardiac output in HFpEF is more complex 
and since HFpEF is a heterogeneous clinical diagnosis, it encompasses a variety of underlying 
pathophysiological processes.
HFpEF is caused by the complex interplay of multiple impairments in ventricular diastolic 
function, adverse cardiac remodeling, stiffening of the ventricles, pulmonary hypertension, 
Comorbid conditions Frequency
Hypertension 60–80%
Ischemic heart disease 35–70%
Diabetes 20–45%
Atrial fibrillation 15–40%
COPD 31%
Renal insufficiency 26%
COPD: Chronic obstructive pulmonary disease.
Table 1.  Comorbid conditions seen in association with HFPEF.
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atrial dysfunction and abnormal ventricular-vascular coupling related to stiffening of the 
 vasculature and hence decreased vascular compliance, endothelial dysfunction, impaired 
vasodilatation and coronary ischemia, impaired renal handling of salt and fluid and impair-
ment of heart rate (HR) reserve [18]. Left ventricular diastolic dysfunction is the result of 
myocardial hypertrophy, fibrosis and/or altered myocyte calcium handling (delayed calcium 
uptake by the myocyte sarcoplasmic reticulum and calcium efflux from the myocyte) [19]. 
The pathophysiology of diastolic dysfunction includes delayed relaxation, impaired LV filling 
and/or increased stiffness. A slowing of the normal diastolic relaxation of the ventricle can in 
turn increase the left ventricular and left atrial pressures [20].
There are a number of causes, which lead to HFpEF. Age seems to be the dominant risk 
factor for HFpEF. Heart failure with preserved EF is exclusively a disease of elderly. As one 
ages, there is an increased collagen deposition with a reduction in the amount of elastin, 
which can lead to increased stiffness of the heart and blood vessels leading to ultimate 
HFpEF. Chronic hypertension, which is highly prevalent in HFpEF, leads to left ventricular 
hypertrophy and increased connective tissue content, both of which decrease cardiac com-
pliance. Due to decreased compliance, in HFpEF LV functions on a steeper diastolic pres-
sure-volume relationship compared with the normal ventricle. This leads to decreased LV 
end-diastolic volumes and a compensatory rise in LV filling pressure to maintain cardiac 
output. This high LV filling pressures lead to fluid accumulation in the lungs, which cause 
dyspnea, which is the common symptom of heart failure. As well as leading to symptoms 
of dyspnea, elevation in LV filling pressures produces secondary pulmonary hypertension 
and atrial remodeling that can predispose a patient to the development of right ventricular 
(RV) dysfunction and atrial fibrillation, respectively. Although epicardial coronary artery 
disease causing ischemic heart disease is less common in patients with HFpEF compared 
to HFrEF, subendocardial ischemia related to increased left ventricular diastolic pressures 
in a left ventricle with concentric remodeling is more common in patients with HFpEF. 
Multiple studies have shown an association between endothelial dysfunction and HFpEF 
and endothelial dysfunction was suggested to be as a prominent determinant of HFpEF 
[21]. Vascular stiffness is also an important contributor to pathophysiological process that 
leads to HFpEF. As a result of ventricular-arterial uncoupling, cardiac output decreases. 
Regardless of EF, ultimate decrease in cardiac output causes activation of neurohormonal 
mechanisms that lead to activation of vasoconstriction, salt and water retention and 
increased diastolic filling pressures [22]. HFpEF patients display neurohormonal profiles 
similar to HFrEF, with elevated circulating neurohormones, such as natriuretic peptides 
and norepinephrine [23].
Chronotropic incompetence (CI) is a potential pathophysiological factor in HFpEF, con-
tributing to reduced exercise capacity. The increase in heart rate as a result of an activity or 
exercise is one of the two main contributors of increased cardiac output to meet the excess 
need of energy consumption. Moreover, the increase in HR is the strongest contributor to 
the ability to perform sustained aerobic exercise [24]. Phan et al. have shown that CI can be 
seen in patients with HFpEF during maximal exercise [25]. In this study, the prevalence of 
CI was 35% in HFpEF subjects. Chronotropic incompetence may be a significant contributor 
to severe, symptomatic exercise intolerance, which is the most common symptom in HFpEF. 
Atrial fibrillation (AF) is also common in patients with diastolic dysfunction and contributes 
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to the pathophysiology of HFpEF. AF eliminates the late diastolic atrial contribution to LV 
filling, upon which patients with diastolic dysfunction are dependent and is poorly tolerated 
leading to both pulmonary edema and decreased cardiac output.
4. Diagnosis
The diagnosis of HFpEF is more challenging than the diagnosis of HFrEF. Part of the chal-
lenge is the fact that the HFpEF is a heterogeneous clinical entity, whose manifestations and 
outcomes remain difficult to be predicted. In essence, it’s a diagnosis of exclusion. According 
to the recent ESC 2016 HF guideline [2], for the diagnosis of HFpEF, three essential criteria 
should be met. Table 2 shows these criteria for diagnosis of HFpEF. As in HFrEF, HFpEF is 
a clinical diagnosis. Symptoms are often nonspecific and do not, therefore, help discriminate 
between HFpEF and HFrEF. Exercise dyspnea may be the only symptom with no detectable 
sign especially in the early stages of HFpEF. Exercise dyspnea is particularly difficult to inter-
pret in elderly and in obese, comprising most of the HFrEF population. Objective evidence of 
reduced exercise capacity provided by cardiometabolic exercise testing with measurement of 
peak exercise oxygen consumption (VO
2max
) or by the 6 min walking test can be used for judg-
ment of exercise dyspnea in the context of HF symptom. Signs of congestive HF such as lung 
crepitations, pulmonary edema, jugular venous distention and ankle edema may not always 
be present, especially in the early stages. The “presence of signs or symptoms of congestive 
heart failure” as the first criterium for the diagnosis of HFpEF is therefore put instead of the 
“presence of signs and symptoms of congestive heart failure” [2].
Once a clinical diagnosis of HF has been made, the presence of HFpEF can be established by 
confirming a normal or near-normal LVEF, often by an echocardiogram. Echocardiography 
is an essential tool in evaluating patients with unexplained dyspnea. Bearing in mind that 
HFpEF is a diagnosis of exclusion, echocardiography should first provide information about 
the left ventricular systolic performance (commonly assessed using ejection fraction), val-
vular disease and pericardial disease. After exclusion of other possible explanations for HF, 
echocardiography should provide evidence of structural heart disease such as left ventricu-
lar hypertrophy, left atrial enlargement and pulmonary hypertension. Diastolic dysfunction 
can also be diagnosed further using the Doppler echocardiography (based on mitral inflow 
1) Symptoms and/or signs of congestive heart failure
2) Non-dilated left ventricle (LV end-diastolic volume index (LVEDVI) < 97 mL/m2) with preserved ejection fraction 
(≥50%)
3) a) Elevated levels of natriuretic peptides
b) At least one additional criterion
i) Relevant structural heart disease (LVH and/or LAD)
ii) Diastolic dysfunction
BNP, B-type natriuretic peptide; HFPEF, heart failure with preserved ejection fraction; LAD, left atrial dilation; LV, left 
ventricular; LVH, left ventricular hypertrophy.
a Signs may not be present in the early stages of HF (especially in HFpEF) and in patients treated with diuretics.
b BNP > 35 pg/ml and/or NT-proBNP > 125 pg/mL.
Table 2. Criteria for the diagnosis of HFPEF.
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 velocities). It is graded based on the ratio of the early, E, to late diastolic, inflow velocity, 
A (mild, moderate and severe) [26]. Grade I is abnormal relaxation pattern (E < A), grade 
II is pseudonormal pattern (E > A), grade III is restrictive pattern (E >> A) and grade IV is 
irreversible restrictive pattern [27]. The pseudonormal stage (grade II), which refers to a 
situation when filling pressures are elevated but the mitral inflow pattern appears normal, is 
creating a state of confusion. Assessment of pulmonary vein flow (PVF) velocity waveforms 
provide information complementary to that obtained from transmitral flow (TMF) patterns. 
Therefore, PVF pattern can be used to differentiate a normal from a pseudonormal TMF 
pattern. Grade III and grade IV diastolic dysfunctions are called restrictive filling dynamics. 
These are both severe forms of diastolic dysfunction and patients tend to have advanced HF 
symptoms at this stage.
Elevated LV filling pressures are the main and essential physiologic consequence of diastolic 
dysfunction. In the presence of symptoms and/or signs of HF and normal or near-normal EF, 
high LV filling pressures help a lot to put the diagnosis of HFpEF. Pulsed-Doppler-derived 
TMF is largely influenced by preload. Left ventricular filling pressures can also be estimated 
by myocardial tissue-Doppler-derived early diastolic annular velocity, designated E′ which 
is, to a large extent, regarded as a preload-independent index of diastolic performance. The 
use of tissue Doppler imaging-derived indices that correct for the influence of myocardial 
relaxation on the load-dependent early diastolic mitral flow E/E′ ratio (i.e., the ratio of mitral 
inflow, E, to early diastolic annular velocity, E′) as a means of estimating LV filling pres-
sure is more reliable. Therefore, noninvasive diagnostic evidence of diastolic LV dysfunc-
tion is preferably derived from myocardial TD. If myocardial TD yields values E/E′ > 15, it 
puts diagnosis of high LV filling pressure. When the ratio is lower than 8, LV filling pres-
sures are considered low. If TD yields an E/E′ ratio suggestive of LV diastolic dysfunction 
but not diagnostic (15 > E/E′ > 8), then additional echo variables are required for diagnostic 
evidence of LV diastolic dysfunction, which include Doppler flow profile of mitral valve or 
pulmonary veins, measurement of LV mass index (LVMi) or left atrium volume index (LAVi), 
electrocardiographic evidence of atrial fibrillation, or high levels of BNP or NT-proBNP. No 
single echocardiography variable is sufficiently accurate to be used in isolation to make a 
diagnosis of LV diastolic dysfunction. Therefore, a comprehensive echocardiography exami-
nation incorporating all relevant two- dimensional and Doppler data is recommended [2]. 
Invasive method of measuring filling pressure is more precise and yields higher diagnostic 
performance but not practical. Invasive diagnostic evidence of diastolic LV dysfunction can 
be obtained by LV end-diastolic pressure (LVEDP) or pulmonary capillary wedge pressure 
(PCWP). Filling pressures are considered elevated when the mean PCWP is >12 mm Hg or 
when the LVEDP is >16 mm Hg.
It is noteworthy that diastolic dysfunction is not always present in HFpEF, being observed 
by echocardiography in only two-thirds of patients at rest [28]. However, many patients with 
HFpEF display elevated LV filling pressures only during the stress of exercise, indicating an 
earlier stage of disease [29]. In such patients, the diagnosis of HFpEF could only be made 
using exercise hemodynamic evaluation using supine bicycle diastolic stress test. After stress, 
an increase in E/E′ and tricuspid regurgitation (TR) velocity indicating a high pulmonary 
artery systolic pressure can truly put the diagnosis of HFpEF [2].
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Biomarkers have been recently used in the diagnostic workup of HF. BNP is synthesized and 
released upon LV wall stretch from increased pressure or volume. The plasma levels of BNP 
are raised in HF regardless of EF. However, natriuretic peptides (NPs) are less elevated in 
HFpEF compared to HFrEF. NPs are an important aid for the diagnosis of HF, especially in the 
non-acute setting when echocardiography is not immediately available. In the Breathing Not 
Properly study, BNP levels at the time of emergency admission were significantly elevated 
in HFpEF, when compared to other causes of dyspnea (median 413 vs. 34 pg/ml, p < 0.001) 
but significantly lower than in patients with HFrEF (median 413 vs. 821 pg/ml, p < 0.001) 
[30]. Many patients with HFpEF display elevated filling pressures only during exercise. This 
intermittent nature of pressure elevation is likely to explain the reduced BNP level observed 
in patients with HFpEF [31].
5. Challenges in the diagnosis of HFpEF
Diagnosis of HFpEF is more difficult than the diagnosis of HFREF because it is largely one of 
the exclusions, i.e., potential noncardiac causes of patients’ symptoms (lung disease, anemia, 
chronic kidney disease, or obesity) that must first be eliminated. For most patients with a 
diagnosis of heart failure but preserved left ventricular systolic function based on symptoms 
and signs of HF which are highly nonspecific and normal EF, the diagnosis of HFpEF is rarely 
needed [5]. Before ascribing symptoms to HFpEF for which there is no evidence-based treat-
ment, we should thoroughly investigate patient for other possible treatable causes of dyspnea 
with calculation of body mass index, pulmonary function testing, exercise electrocardiogra-
phy and probably stress echocardiography.
The diagnostic criteria put forward for HFpEF has some important pitfalls. In HFpEF, exer-
tional dyspnea is frequently the earliest symptom due to increased LV filling pressures ensu-
ing some degree of pulmonary congestion. Since many patients with HFPEF present with 
dyspnea and no signs of fluid overload, exertional dyspnea was considered sufficient clinical 
evidence to suggest the presence of clinical heart failure in the recent guidelines [2]. Keeping 
in mind that dyspnea is a ubiquitous complaint especially in elderly and obese who represent 
a large proportion of HFpEF patients and other comorbid conditions such as chronic obstruc-
tive pulmonary disease and renal insufficiency which are usually present concomitant with 
HFpEF, dyspnea cannot be a reliable diagnostic criteria without objective evidence of reduced 
exercise performance provided by metabolic exercise testing. Meanwhile, because early signs 
and symptoms of HFpEF such as exercise dyspnea may also be the presenting symptoms of 
other alternative conditions or diseases, delayed diagnosis has also been a matter.
Diastolic dysfunction as assessed noninvasively by echocardiography is highly prevalent in 
elderly population who has no symptoms attributable to HF. This condition suggests some 
controversy regarding the accuracy of noninvasive measures of diastolic function by echo-
cardiography [32]. Assessment should take into consideration patients’ ages and heart rates 
(mitral E, E/A ratio and annular e´ decrease with increasing heart rate). Specifically, in older 
individuals without histories of cardiovascular disease, caution should be exercised before 
concluding that grade I diastolic dysfunction is present. Because the majority of subjects aged 
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over 60 years without histories of cardiovascular disease have E/A ratios, <1 and E decelera-
tion time (EDT) > 200 ms, such values in the absence of further indicators of LV dysfunction 
(e.g., LV hypertrophy and LA enlargement), can be considered normal for age. In other words, 
echocardiogram suggesting diastolic dysfunction on the basis of an abnormal E/A ratio is not 
diagnostic and represents insufficient investigation. Second, the echocardiographic markers 
of diastolic dysfunction may be absent in a significant proportion of patients diagnosed with 
HFpEF.
Natriuretic peptides could give inconclusive results in a number of situations. In normal indi-
viduals, the concentration of NT-proBNP rises with age and is higher in women than in men 
[33]. Therefore, age-stratified cutoff points for NT-proBNP (≥450 for ages < 50 years, ≥900 for 
50–75 years and ≥1800 pg/mL for >75 years) were shown to perform the best diagnostic per-
formance for rule in acute HF setting [34]. Beyond HF, a number of cardiopulmonary disor-
ders are also associated with elevated BNP or NT-proBNP values: acute coronary syndrome, 
myocarditis, valvular heart disease, hypertrophic cardiomyopathy, cardiotoxic drugs, atrial 
fibrillation, or flutter and right ventricular dysfunction in the setting of significant pulmonary 
disease (pulmonary hypertension, pulmonary embolism). Other conditions that are associ-
ated with higher BNP or NT-proBNP levels may be related to comorbidities such as advanced 
age, renal dysfunction, stroke, sepsis and other high output states. It should be kept in mind 
that plasma levels of BNP rise independently of LV filling pressures once glomerular filtration 
rate falls below 60 mL/min because renal dysfunction is highly prevalent in HFpEF popula-
tion. AF also confounds the utility of BNP for diagnosing HFpEF [35, 36].
6. Treatment
Prevention of HFpEF through treatment of risk factors (e.g., hypertension, diabetes and coro-
nary artery disease) especially at early stages is effective and still the most important part of 
management of HFpEF since specific treatments are yet to be discovered [37]. Hypertension 
antedates the development of HFpEF in nearly 90% of the cases and it confers a two- to three-
fold increased risk of developing HFpEF [38]. Therefore, strict control of hypertension will 
inevitably prevent development of HFpEF. Improving cardiorespiratory fitness among low-
fit sedentary individuals by exercise training could be another preventive approach against 
HFpEF. And, targeting obesity in the early childhood will also prevent development of 
HFpEF in the future.
As a non-pharmacologic therapy, exercise training has clearly been shown to benefit cardiore-
spiratory health in patients with HFrEF. Recent studies have addressed the effects of exercise 
training in patients with HFpEF. Although the effects on HF-related mortality and hospital-
izations were not studied, these reports showed that moderate supervised exercise program 
had positive effects on the quality of life, exercise tolerance but not left ventricular EF [39, 
40]. No pharmacologic therapy has been shown to be effective in improving outcomes in 
patients with heart failure with HFpEF. There is no single explanation for the negative results 
of past HFpEF trials. Potential contributors include an incomplete understanding of HFpEF 
pathophysiology, inadequate diagnostic criteria, recruitment of patients without true HF or at 
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early stages of the syndrome, poor matching of therapeutic mechanisms and primary patho-
physiological processes, suboptimal study designs, inadequate statistical power, or patient 
heterogeneity [41]. Another possible explanation is the fact that non-cardiovascular mortality 
is higher in HFpEF than HFrEF highlighting one of the difficulties in the development of an 
effective therapeutic strategy in the overall patients with HFpEF.
The treatment recommendations from the American Heart Association have set four goals 
in the management of these patients: (a) control of hypertension, (b) control of heart rate 
especially in the patients with atrial fibrillation, (c) control of pulmonary and peripheral 
edema and (d) prevention of myocardial ischemia [1]. 2013 ACC/AHA Guideline on HF had 
only two class I recommendations for HFpEF treatment. One of them is the use of diuret-
ics in order to reduce volume overload and improve dyspnea. The second one is the con-
trol of blood pressure. The guideline also recommends revascularization in patients whom 
symptoms or demonstrable ischemia are thought to contribute HF symptoms as class II 
recommendation. Management of AF is another class II recommendation of the American 
guideline. The guideline does not underscore rhythm control or rate control in HFpEF since 
there was no specific trial comparing these two strategies in HFpEF until now. The recent 
2016 European Society of Cardiology (ESC) Guideline could not make any further recom-
mendations on top of 2013 American guideline in this regard except recommending screen-
ing patients with HFpEF for both cardiovascular and non-cardiovascular comorbidities, 
which then should be treated accordingly [2].
Table 3 summarizes the major clinical trials that have evaluated the efficacy of various thera-
peutic drugs in patients with HFpEF. The renin-angiotensin-aldosterone system (RAAS) is 
involved in many of the pathophysiological processes associated with this disease (includ-
ing hypertension, left ventricular hypertrophy, myocardial fibrosis and vascular dysfunction) 
and inhibitors of this system can prevent neurohormonal activation and prevent ventricular 
remodeling [22]. RAAS blockers have been long time investigated whether they could be 
effective therapeutic option for these patients. Three large trials have evaluated inhibitors of 
the RAAS in patients with HFpEF but none of them proved to be beneficial. The Candesartan 
in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM)-preserved 
trial evaluated the effect of candesartan on elderly patients with HFpEF [42]. Candesartan 
showed no significant reduction of cardiovascular death but showed significant reduction in 
HF hospitalization. The Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF) 
trial was a randomized placebo-controlled trial which evaluated the effect of perindopril on 
patients with HFpEF [43]. At the end of the study, perindopril showed no significant effect 
on mortality, but showed significant benefit in unplanned HF hospitalization in 1 year. The 
Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE) investigated 
the effect of the angiotensin-receptor blocker irbesartan on mortality and cardiovascular mor-
bidity in patients with HFpEF [44]. Treatment with irbesartan did not reduce the risk of death 
or hospitalization for cardiovascular causes among HFpEF patients nor did it improve any of 
the secondary clinical outcomes, including disease-specific quality of life.
The Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalization in 
Seniors (SENIORS) with Heart Failure, which consist of both HFrEF and HFpEF patients, 
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Trial Year Intervention No. of subjects Key inclusion criteria Key exclusion criteria Outcome(s) Findings
CHARM-
preserved
2003 Candesartan 
versus placebo
3023 Age > 18 years
LVEF > 40%
NYHA class II–IV
Persistent systolic or 
diastolic hypertension
Hospitalization
Mortality
No effect on mortality
Slight reduction in HF 
hospitalization
PEP-CHF 2006 Perindopril versus 
placebo
846 >40% Rehospitalization at 
1 year
Mortality
No effect on mortality
Decreased 1 year 
rehospitalization and 
increased exercise 
capacity
SENIORS 2006 Nebivolol versus 
placebo
752 >35% CV-related 
hospitalization
Mortality
No effect on mortality 
or hospitalization in 
patients with EF > 40%
I-PRESERVE 2008 Irbesartan versus 
placebo
4128 Age > 60 years
LVEF > 45%
NYHA class II–IV and 
HF hospitalization < 
6 months or NYHA 
class III/IV and 
abnormal CXR, ECG, or 
echocardiogram
AF with resting heart 
rate > 120 beats/min
Cor pulmonale
Clinically significant 
pulmonary disease
Significant valvular 
disease
Hb < 11 g/dl
BP > 160/95 mm Hg 
despite therapy
Mortality
Hospitalization
No effect on mortality 
or CV hospitalization
ALDO-DHF 2013 Spironolactone 
versus placebo
422 Age > 50
LVEF > 50%
NYHA class II or III
Echo evidence of 
diastolic dysfunction 
(grade ≥I)
Atrial fibrillation at 
presentation, maximum 
exercise capacity (peak 
VO
2
) < 25 mL/kg/min
Significant CAD
Significant pulmonary 
disease
GFR < 30 ml/min
MI or CABG in past 3 
months
Improvement in 
diastolic function 
(E/e′)
And maximal 
exercise capacity 
(VO
2
)
Improved diastolic 
function
Induced reverse 
remodeling
Improved 
neuroendocrine 
activation but not 
improve heart failure 
symptoms or quality 
of life and slightly 
reduced 6 min walk 
distance
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Trial Year Intervention No. of subjects Key inclusion criteria Key exclusion criteria Outcome(s) Findings
TOPCAT 2014 Spironolactone 
versus placebo
3445 Age > 50
LVEF > 45%
≥1 HF hospitalization in 
the previous 12 months
or
BNP ≥100 pg/mL or 
NT-proBNP ≥360 pg/
mL
Controlled systolic 
blood pressure asystolic 
blood pressure < 
140 mm Hg or 140 
to 160 mm Hg if on 
≥3 antihypertensive 
medications
COPD
Infiltrative of 
hypertrophic CMP
Significant valve 
disease
AF with resting heart 
rate >90 beats/min
GFR < 30 ml/min
MI or CABG in past 3 
months
PCI in past 30 days
Death from 
cardiovascular 
causes
Aborted cardiac 
arrest
Hospitalization 
for HF
No effect on 
cardiovascular death
Reduced HF 
hospitalization
Induced an increase in 
serum creatinine and 
potassium levels
PARAMOUNT 2012 LCZ 696 versus 
valsartan
301 Age > 40 years
EF > 45%,
NYHA class II and III,
Elevations of 
NT-proBNP > 400 pg/
ml
LVEF < 45%
Isolated right heart 
failure owing to 
pulmonary disease
Dyspnea from non 
cardiac causes
GFR < 30 ml/min
Primary valvular or 
myocardial diseases
Coronary or 
cerebrovascular 
diseases needing 
revascularization 
within 3 months
Reduction in 
NT-proBNP at 12 
weeks
NYHA functional 
class and LA 
dimension at 36 
weeks
Reduced natriuretic 
peptides at 12 weeks
Improved NYHA class 
and improved left 
atrial dimensions at 36 
weeks
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Trial Year Intervention No. of subjects Key inclusion criteria Key exclusion criteria Outcome(s) Findings
RELAX HF 2013 versus placebo 216 LVEF > 45%
NYHA II–IV
Previous hospitalization 
for HF
Increased pro NT-pro 
BNPİ or invasively 
measured high filling 
pressure
Peak VO
2
 < 60%
Any obstacle for 
exercise testing
Need for nitrate 
therapy
Primary pulmonary
Arteriopathy
Primary valve disease
Other causes of 
dyspnea
Exercise capacity
Clinical status
No effect on exercise 
capacity or clinical 
status
All abbreviations are explained in the text of the manuscript.
Table 3. Major clinical trials in patients with HFPEF.
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showed that a beta1-blocker with nitric oxide-potentiating vasodilatory effect, nebivolol, 
reduces hospitalization in older HF patients with preserved and reduced EF but had no effect 
on mortality [45]. Preserved EF was considered as EF > 35% which constitutes 35% of the 
overall study population. The proportion of patients with truly preserved EF (>50%) was very 
small. Therefore, although the overall study suggests a modest benefit of nebivolol, the results 
can’t be extrapolated to true HFpEF patients.
The mineralocorticoid receptor antagonists spironolactone and eplerenone have been shown 
to reduce total and cardiovascular mortality across the spectrum of HFrEF and in patients 
with acute myocardial infarction complicated by left ventricular dysfunction and heart fail-
ure [46–48]. By reducing cardiac fibrosis and hypertrophy, aldosterone antagonists have the 
potential to be beneficial in heart failure with preserved ejection fraction (HFpEF) [49]. In the 
Aldosterone Receptor Blockade in Diastolic Heart Failure (Aldo-DHF) trial, the effect of spi-
ronolactone on diastolic function and exercise capacity in patients with HFpEF was tested [50]. 
The left ventricular end-diastolic filling, left ventricular remodeling (LV mass index decreased 
but LA diameter not changed) and neurohumoral activation (NT pro-BNP decreased) were 
improved with spironolactone, demonstrating aldosterone effect on improving diastolic func-
tion and reversing cardiac remodeling. However, spironolactone had no effect on functional 
exercise capacity in this trial. Upon positive findings with spironolactone on diastolic func-
tion and cardiac remodeling, the Treatment of Preserved Cardiac Function Heart Failure with 
an Aldosterone Antagonist (TOPCAT) trial was planned to investigate whether treatment 
with spironolactone would reduce morbidity and mortality in patients with HFpEF [51]. The 
TOPCAT trial found that, compared to placebo, spironolactone did not reduce the compos-
ite of cardiovascular death, aborted cardiac arrest or heart failure hospitalization in patients 
with HFpEF but reduced the individual component of heart failure hospitalization. However, 
there was a significant interaction between treatment effect and patient recruitment strategy 
(natriuretic peptides vs. hospitalization with HF). In patients recruited based on previous 
hospitalization, spironolactone had no effect on outcome, whereas in patients recruited based 
on high BNP, spironolactone showed a benefit. This difference highlights the importance of 
patient selection criteria and recruitment of patients with true HFpEF for future trials. The 
efficacy of eplerenone on 6 min walking distance was evaluated in a single-center, random-
ized study. It was found that after 24 weeks of eplerenone treatment, there was no change in 6 
min walk distance [52]. Another randomized, clinical study evaluated the effect of eplerenone 
on the primary outcome comprising of death from cardiovascular causes, nonfatal reinfarc-
tion, hospitalization for unstable angina, or decompensation of heart failure [53]. Eplerenone 
was found to have no significant effect on the primary outcome.
Phosphodiesterase-5 (PDE-5) metabolizes the nitric oxide and natriuretic peptide systems’ 
second messenger cyclic guanosine monophosphate and thus may limit beneficial nitric oxide 
and natriuretic peptide actions in the heart, vasculature and kidneys. Phosphodiesterase type 
5 inhibitors (PDE5I) increase cGMP levels by blocking their catabolism. PDE5I may reduce 
ventricular-vascular stiffening, antagonize maladaptive chamber remodeling, improve endo-
thelial function, reduce pulmonary vascular resistance and enhance renal responsiveness 
to natriuretic peptides [54, 55]. Phosphodiesterase type 5 inhibitor, sildenafil, was proved 
to improve hemodynamic parameters in HFrEF patients [56]. The Phosphodiesterase-5 
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Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure with Preserved 
Ejection Fraction (RELAX) trial was conducted to investigate the effect of the PDE-5 inhibi-
tor, on exercise capacity in HFpEF [57]. At the end of 24 weeks, long-term PDE-5 inhibition in 
HFpEF had no effect on maximal or submaximal exercise capacity, clinical status, quality of 
life, left ventricular remodeling, diastolic function parameters, or pulmonary artery systolic 
pressure.
It is known that in both the failing heart and in case of ischemia, the late sodium current 
is increased, leading to an Na+ accumulation in cardiac myocytes [58]. The increased Na+ 
concentration reverses the mode direction of the Na+/Ca2+exchanger, contributing to a Ca2+ 
overload in the cell. Increased diastolic Ca2+ impairs relaxation leading to diastolic dys-
function. By inhibiting the late Na+ channel, ranolazine is theoretically expected to prevent 
(or reduce) sodium accumulation in the myocyte. This should improve calcium extrusion 
through the Na+/Ca2+ exchanger and thereby improve relaxation of the myocardium. The 
Ranolazine for the Treatment of Diastolic Heart Failure (RALI-DHF) study was designed to 
evaluate the effect of ranolazine versus placebo on hemodynamics, measures of diastolic dys-
function and biomarkers in 20 patients with HFpEF [59]. After 30 min of infusion, significant 
decreases from baseline were observed in LVEDP and PCWP in the ranolazine group, but not 
in the placebo group. However, ranolazine had no effect on invasively determined relaxation 
parameters and the noninvasive E/E′ ratio.
In the recent PARADIGM-HF trial, the patients taking LCZ 696 showed steep reduction in the 
primary endpoint of CV death/heart failure hospitalization [60]. McMurray et al. noted that 
a subgroup of patients in the reduced EF spectrum’s high end, i.e., LVEF approaching 40%, 
also benefits to the same extent as the overall study group [61]. Solomon et al. conducted pro-
spective comparison of Angiotensin Receptor Neprilysin Inhibitor (ARNi) with Angiotensin 
Receptor Blocker (ARB) on Management of heart failure with preserved ejection fraction, 
PARAMOUNT trial, a double-blind randomized trial in 301 patients with heart failure with 
HFpEF, which compared LCZ696 with valsartan [62]. The primary endpoint, the decline in 
NT-proBNP, was significantly greater in the LCZ696 group than in the valsartan group. After 
36 weeks, both left atrial volume and dimension, which reflect left ventricular filling pressure, 
also declined more with LCZ696 and there was greater improvement in the New York Heart 
Association (NYHA) functional class with LCZ696 than with valsartan.
These encouraging results with LCZ696 have provided the rationale for a large outcomes trial 
in HFpEF. Prospective Comparison of ARNI with ARB Global Outcomes in Heart Failure 
with Preserved Ejection Fraction (PARAGON-HF) will use a similar overall study design to 
that of PARAMOUNT to determine whether LCZ696 can reduce cardiovascular death or total 
HF hospitalizations in patients with HFpEF. PARAGON-HF will enroll 4,300 patients with 
HFpEF until the end of 2016.
7. Future perspectives
Diagnosis of HFpEF should only be made after complete workup and if noninvasive diagnos-
tic data comprising of LA dilation, diastolic dysfunction and high natriuretic peptide levels, 
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or invasively measured high LVEDP or PCWP proves indisputably the presence of high LV 
filling pressure. Only when more specific diagnostic criteria have emerged over time and 
started to be used in the clinical trials for patient recruitment, we will see improvements in 
outcome for this common and growing form of cardiac disease. The strategy of a tailored 
“precision” approach considering both the comorbidities concomitant with HFpEF and 
underlying pathophysiologic mechanism of reduced cardiac and vascular reserve will lead to 
improvement in prognosis of HFpEF.
Author details
Hakan Altay* and Seckin Pehlivanoglu
*Address all correspondence to: sakaltay@yahoo.com
Cardiology Department, Faculty of Medicine, Baskent University, Istanbul Hospital, Turkey
References
[1] Yancy CW, Jessup M, Wright RS, et al. ACCF/AHA guideline for the management of 
heart failure: a report of the American College of Cardiology Foundation/American 
Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240–e327.
[2] Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-
Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis 
JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; 
Authors/Task Force Members; Document Reviewers. 2016 ESC guidelines for the diag-
nosis and treatment of acute and chronic heart failure: the task force for the diagnosis 
and treatment of acute and chronic heart failure of the European Society of Cardiology 
(ESC). Developed with the special contribution of the Heart Failure Association (HFA) 
of the ESC. Eur J Heart Fail. 2016;18(8):891–975.
[3] Senni M, Tribouilloy CM, Rodeheffer RJ, Jacobsen SJ, Evans JM, Bailey KR, Redfield 
MM. Congestive heart failure in the community: a study of all incident cases in Olmsted 
county, Minnesota, in 1991. Circulation. 1998;98:2282–2289.
[4] Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in 
prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 
2006;355:251–259.
[5] Caruana L, Petrie MC, Davie AP, McMurray JJ. Do patients with suspected heart failure 
and preserved left ventricular systolic function suffer from “diastolic heart failure” or 
from misdiagnosis? A prospective descriptive study. BMJ. 2000;321:215–219.
[6] Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP. Outcome of 
heart failure with preserved ejection fraction in a population- based study. N Engl J Med. 
2006;355:260–269.
Heart Failure with Preserved Ejection Fraction
http://dx.doi.org/10.5772/66758
53
[7] Bursi F., et al. Systolic and diastolic heart failure in the community. JAMA. 2006; 
296:2209–2216.
[8] Owan TE, Hodge DO, Davie AP, et al. Epidemiology of chronic heart failure. Prog 
Cardiovasc Dis. 2005;47:320–332.
[9] Ceia F, Fonseca C, Mota T, Morais H, Matias F, de Sousa A, et al. Prevalence of chronic 
heart failure in southwestern Europe: the EPICA study. Eur J Heart Fail. 2002;4:531–539. 
This study reports the prevalence of HFpEF in Portuguese reporting a higher prevalence 
than HFrEF.
[10] Hogg K, Swedberg K, McMurray JJ. Heart failure with preserved left ventricular sys-
tolic function; epidemiology, clinical characteristics and prognosis. J Am Coll Cardiol. 
2004;43:317–327.
[11] Lenzen MJ, Scholte op Reimer WJ, Boersma E, et al. Differences between patients with a 
preserved and a depressed left ventricular function: a report from the EuroHeart Failure 
Survey. Eur Heart J. 2004;25:1214–1220.
[12] Solomon SD, Wang D, Finn P, Skali H, Zornoff L, McMurray JJV, Swedberg K, 
Yusuf S, Granger CB, Michelson EL, Pocock S, Pfeffer MA. Effect of candesartan on 
cause-specific mortality in heart failure patients: the Candesartan in Heart Failure 
Assessment of Reduction in Mortality and Morbidity (CHARM) program. Circulation. 
2004;110:2180–2183.
[13] Zile MR, Gaasch WH, Anand IS, et al. Mode of death in patients with heart failure and 
a preserved ejection fraction: results from the Irbesartan in heart failure with preserved 
ejection fraction study (I-Preserve) trial. Circulation. 2010;121:1393–1405.
[14] Poole-Wilson PA, Uretsky BF, Thygesen K, Cleland JGF, Massie BM, Rydén L. Mode of 
death in heart failure: findings from the ATLAS trial. Heart. 2003;89:42–48.
[15] Hamaguchi S, Kinugawa S, Sobirin MA, Goto D, Tsuchihashi-Makaya M, Yamada S, 
et al. Mode of death in patients with heart failure and reduced versus preserved ejec-
tion fraction: report from the registry of hospitalized heart failure patients. Circ J. 
2012;76(7):1662–1669.
[16] Campbell RT, Jhund PS, Castagno D, Hawkins NM, Petrie MC, McMurray JJ. What have 
we learned about patients with heart failure and preserved ejection fraction from DIG-
PEF, CHARM-preserved and I-PRESERVE? J’Coll Cardiol. 2012;60(23):2349–2356.
[17] Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC. Clinical presenta-
tion, management and in-hospital outcomes of patients admitted with acute decom-
pensated heart failure with pre-served systolic function: a report from the Acute 
Decompensated Heart Failure National Registry (ADHERE) database. J Am Coll 
Cardiol. 2006;47(1):76–84.
[18] Kass DA, Bronzwaer JG, Paulus WJ. What mechanisms underlie diastolic dysfunction in 
heart failure? Circ Res. 2004;94:1533–1542.
Cardiomyopathies - Types and Treatments54
[19] Borlaug BA, Kass DA. Mechanisms of diastolic dysfunction in heart failure. Trends 
Cardiovasc Med. 2006;16:273–279.
[20] Oxenham HC, Young AA, Cowan BR, et al. Age related changes in myocardial relax-
ation using three dimensional tagged magnetic resonance imaging. J Cardiovasc Magn 
Reson. 2003;5:421–430.
[21] Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection frac-
tion: comorbidities drive myocardial dysfunction and remodeling through coronary 
microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263–271.
[22] Hogg K, McMurray J. Neurohumoral pathways in heart failure with preserved systolic 
function. Prog Cardiovasc Dis. 2005;47:357–366.
[23] Kitzman DW, Little WC, Brubaker PH, et al. Pathophysiological characteriza-
tion of isolated diastolic heart failure in comparison to systolic heart failure. JAMA. 
2002;288:2144–2150.
[24] Higginbotham MB, Morris KG, Williams RS, McHale PA, Coleman RD, Cobb FR. 
Regulation of stroke volume during submaximal and maximal upright exercise in 
 normal man. Circ Res. 1986;58:281–291.
[25] Phan TT, Shivu GN, Abozuia K, et al. Impaired heart rate recovery and chronotropic 
incompetence in patients with heart failure with pre- served ejection fraction. Circ Heart 
Fail. 2010;3:29–34.
[26] Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evalua-
tion of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr. 
2009;22(2):107–133.
[27] Murata K. Predictive significance of evaluation of left ventricular diastolic function in 
patients with heart failure. Rinsho Byoki. 2010;58:792–798.
[28] Shah AM, et al. Cardiac structure and function in heart failure with preserved ejection 
fraction: baseline findings from the echocardiographic study of the treatment of pre-
served cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail. 
2014;7:104–115.
[29] Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM. Exercise hemodynam-
ics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart 
Fail.2010;3:588–595.
[30] Maisel AS, McCord J, Nowak RM, et al. Bedside B type natriuretic peptide in the emer-
gency diagnosis of heart failure with reduced or preserved ejection fraction. Results from 
the Breathing Not Properly Multinational Study. J Am Coll Cardiol. 2003;41:2010–2017.
[31] Anjan VY, et al. Prevalence, clinical phenotype and outcomes associated with normal 
B-type natriuretic peptide levels in heart failure with preserved ejection fraction. Am J 
Cardiol. 2012;110:870–876.
Heart Failure with Preserved Ejection Fraction
http://dx.doi.org/10.5772/66758
55
[32] Tschöpe C, Paulus WJ. Doppler echocardiography yields dubious estimates of left ven-
tricular diastolic pressures. Circulation. 2009;120:810–820.
[33] McDonagh TA, Holmer S, Raymond I, Luchner A, Hildebrant P, Dargie HJ. NT-proBNP 
and the diagnosis of heart failure: a pooled analysis of three European epidemiological 
studies. Eur J Heart Fail. 2004;6:269–273.
[34] Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and 
short-term prognosis in acute destabilized heart failure: an international pooled analy-
sis of 1256 patients: The International Collaborative of NT-proBNP Study. Eur Heart J. 
2006;27:330–337.
[35] Tsutamoto T, Wada A, Sakai H, Ishikawa C, Tanaka T, Hayashi M, Fujii M, Yamamoto T, 
Dohke T, Ohnishi M, Takashima H, Kinoshita M, Horie M. Relationship between renal 
function and plasma brain natriuretic peptide in patients with heart failure. J Am Coll 
Cardiol. 2006;47:582–586.
[36] Knudsen CW, Omland T, Clopton P, et al. Impact of atrial fibrillation on the diag-
nostic performance of B type natriuretic peptide concentration in dyspneic patients: 
an analysis from the breathing not properly multinational study. J Am Coll Cardiol. 
2005;46(5):838–844.
[37] Schocken DD, Benjamin EJ, Fonarow GC, Krumholz HM, Levy D, Mensah GA, Narula 
J, Shor ES, Young JB, Hong Y. Prevention of heart failure: a scientific statement from 
the American Heart Association Councils on Epidemiology and Prevention, Clinical 
Cardiology, Cardiovascular Nursing and High Blood Pressure Research; Quality 
of Care and Outcomes Research Interdisciplinary Working Group; and Functional 
Genomics and Translational Biology Interdisciplinary Working Group. Circulation. 
2008;117:2544–2565.
[38] Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, et al. The 
seventh report of the joint national committee on prevention, detection, evaluation and 
treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289:2560–2572.
[39] Kitzman DW, Brubaker PH, Morgan TM, Stewart KP, Little WC. Exercise training in 
older patients with heart failure and preserved ejection fraction: a randomized, con-
trolled, single-blind trial. Circ Heart Fail. 2010;3:659–667.
[40] Kitzman DW, Brubaker PH, Herrington DM, Morgan TM, Stewart KP, Hundley WG, 
et al. Effect of endurance exercise training on endothelial function and arterial stiffness 
in older patients with heart failure and preserved ejection fraction: a randomized, con-
trolled, single-blind trial. J Am Coll Cardiol. 2013;62:584–592.
[41] Paulus WJ, van Ballegoij JJ. Treatment of heart failure with normal ejection fraction: an 
inconvenient truth! J Am Coll Cardiol. 2010;55:526–537.
[42] Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic 
heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved 
trial. Lancet. 2003;362:777–781.
Cardiomyopathies - Types and Treatments56
[43] Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in 
elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338–2345.
[44] Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR ander-
son S, Donovan M, Iverson E, Staiger C, Ptaszynska A; I-PRESERVE Investigators. 
Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 
2008;359(23):2456–2467.
[45] Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et 
al. Randomized trial to determine the effect of nebivolol on mortality and cardiovas-
cular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 
2005;26:215–225.
[46] Pitt B, Zannad F, Remme WJ, et al.; Randomized Aldactone Evaluation Study 
Investigators. The effect of spironolactone on morbidity and mortality in patients with 
severe heart failure. N Engl J Med. 1999;341(10):709–717.
[47] Zannad F, McMurray JJ, Krum H, et al.; EMPHASIS-HF Study Group. Eplerenone in 
patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11–21.
[48] Pitt B, Remme W, Zannad F, et al.; Eplerenone Post-Acute Myocardial Infarction Heart 
Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone 
blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl 
J Med. 2003;348(14):1309–1321.
[49] Lacolley P, Safar ME, Lucet B, Ledudal K, Labat C, Benetos A. Prevention of aor-
tic and cardiac fibrosis by spironolactone in old normotensive rats. J Am Coll Cardiol. 
2001;37:662–667.
[50] Edelmann F, Schmidt AG, Gelbrich G, et al. Rationale and design of the “Aldosterone 
Receptor Blockade in Diastolic Heart Failure” trial: a double-blind, randomized, pla-
cebo-controlled, parallel group study to determine the effects of spironolactone on exer-
cise capacity and diastolic function in patients with symptomatic diastolic heart failure 
(Aldo-DHF). Eur J Heart Fail. 2010;12(8):874–882.
[51] Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, 
Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O’Meara E, 
Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer MK, Yang S, McKinlay 
SM. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 
2014;370:1383–1392.
[52] Deswal A, Richardson P, Bozkurt B, Mann DL. Results of the randomized aldosterone 
antagonism in heart failure with preserved ejection fraction trial (RAAM-PEF). J Card 
Fail. 2011;17:634–642.
[53] Kampourides K, Tziakas D, Chalikias G, et al. Usefulness of matrix metalloprotein-
ase-9 plasma levels to identify patients with preserved left ventricular systolic func-
tion after acute myocardial infarction who could benefit from eplerenone. Am J Cardiol. 
2012;110:1085–1091.
Heart Failure with Preserved Ejection Fraction
http://dx.doi.org/10.5772/66758
57
[54] Vlachopoulos C, Hirata K, O’Rourke MF. Effect of on arterial stiffness and wave reflec-
tion. Vasc Med. 2003;8:243–248.
[55] Katz SD, Balidemaj K, Homma S, Wu H, Wang J, Maybaum S. Acute type 5 phosphodi-
esterase inhibition with enhances flow-mediated vasodilation in patients with chronic 
heart failure. J Am Coll Cardiol. 2000;36:845–851.
[56] Lewis GD, Shah R, Shahzad K, et al. improves exercise capacity and quality of life in 
patients with systolic heart failure and secondary pulmonary hypertension. Circulation. 
2007;116(14):1555–1562.
[57] Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, 
Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, 
O’Connor CM, Felker GM, Goldsmith SR, Bart BA, McNulty SE, Ibarra JC, Lin G, Oh JK, 
Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, 
Braunwald E; RELAX Trial. Effect of phosphodiesterase-5 inhibition on exercise capacity 
and clinical status in heart failure with preserved ejection fraction: a randomized clinical 
trial. JAMA. 2013;309(12):1268–1277
[58] Valdivia CR, Chu WW, Pu J, et al. Increased late sodium current in myocytes from a canine 
heart failure model and from failing human heart. J Mol Cell Cardiol. 2005;38:475–483.
[59] Acobshagen C, Belardinelli L, Hasenfuss G, Maier LS. Ranolazine for the treatment of 
heart failure with preserved ejection fraction: background, aims and design of the RALI-
DHF study. Clin Cardiol. 2011;34:426–432.
[60] McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi 
VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. 
Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 
2014;371:993–1004.
[61] Solomon S, Packer M, Zile M, et al. The angiotensin receptor neprilysin inhibitor LCZ696 
is effective across the spectrum of ejection fraction in heart failure with reduced ejection 
fraction. J Card Fail. 2015;21:S45.
[62] Solomon SD, Zile M, Pieske B, et al.; for the Prospective comparison of ARNI with ARB 
on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) 
Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with 
preserved ejection fraction: a phase 2 double-blind randomized controlled trial. Lancet. 
2012;380:1387–1395.
Cardiomyopathies - Types and Treatments58
